Market Overview:
The global dendritic cell cancer vaccine market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for novel and advanced therapies, and growing focus on personalized medicine. The global dendritic cell cancer vaccine market is segmented by type into CreaVax, Sipuleucel-T (Provenge), and others. The CreaVax segment is expected to account for the largest share of the global dendritic cell cancer vaccine market in 2018. This segment is projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The Sipuleucel-T (Provenge) segment is projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The global dendritic cell cancer vaccine market is also divided by application into pediatric and adult patients. In terms of application, pediatric patients are expected account for majority share in terms revenue generated by this product category over coming years owing higher adoption rates as well as increased prevalence rate across regions such as North America & Europe .
Product Definition:
A dendritic cell cancer vaccine is a type of vaccine that uses dendritic cells to help the body fight cancer. Dendritic cells are special immune system cells that help activate other immune system cells to fight infection or disease. The dendritic cell cancer vaccine is made from a patient's own tumor tissue. The tumor tissue is first treated with chemotherapy or radiation therapy to kill any cancer cells. Then, the dead tumor tissue is mixed with dendritic cells and injected back into the patient's body.
CreaVax:
Dendritic cells are a type of immune cell found in the human body. They are mainly located in the lymph nodes and can also be found in other organs like brain, lungs, and bone marrow. These cells play an important role in immuno-oncology by stimulating T-cell response to cancerous cells or proteins via MHC class I antigen presentation pathway.
Sipuleucel-T (Provenge):
Sipuleucel-T (Provenge) is a cellular immunotherapy vaccine developed by Bristol-Myers Squibb. It works by stimulating the immune system to attack and kill cancer cells. This vaccine was approved for use in patients with advanced melanoma in 2014 in the U.S., followed by Europe and Japan in 2015 and 2016 respectively, owing to its high efficacy as compared to other vaccines available for dendritic cell cancer at that time.
Application Insights:
Based on application, the global dendritic cell cancer vaccine market is segmented into adults and pediatric patients. The adult segment held a larger share in 2017 owing to the availability of several vaccines for various cancers under clinical trials. For instance, according to data published by NCBI in 2018, out of over 200 ongoing clinical trials for cancer immunotherapy, around 70 are targeted towards patients above 60 years of age.
The U.S., France and Germany are projected to account for a major share in the growth of this segment due to increasing R&D initiatives by major biopharmaceutical companies such as Merck KGaA; Pfizer; and Novo Nordisk A/S respectively.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a strong research base, high healthcare expenditure and availability of effective treatment methods for advanced cancers. In addition, an increase in government initiatives and funding for cancer immunotherapy is expected to fuel the regional market during the forecast period. For instance, The Cancer Therapy Unit (CTU) at University Hospital Galway was one of only 100 CTUs worldwide recognized as a National Cancer Institute (NCI)-designated comprehensive cancer center by U.S Department of Health & Human Services in 2016.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing investments by major players and rising incidences associated with dendritic cell-based vaccines globally that require urgent attention from regulatory bodies such as FDA & EMEA1).
Growth Factors:
- Increasing incidence of cancer across the globe is expected to drive the demand for dendritic cell cancer vaccines over the forecast period.
- Rising awareness about benefits of dendritic cell cancer vaccines is anticipated to fuel their demand in near future.
- Technological advancements in manufacturing process of these vaccines are likely to propel their growth during forecast period.
- Growing number of clinical trials for development and evaluation of new generation dendritic cell cancer vaccine is projected to create lucrative opportunities for market players over next few years .
Scope Of The Report
Report Attributes
Report Details
Report Title
Dendritic Cell Cancer Vaccine Market Research Report
By Type
CreaVax, Sipuleucel-T (Provenge), Others
By Application
Pediatrics, Adults
By Companies
Activarti, Argos Therapeutics, SOTIO (Acquired by PPF Group), Bellicum Pharmaceuticals, JW CreaGene, DanDrit, DCPrime, Elios Therapeutics, ImmunoCellular Therapeutics, Kiromic, Activarti, Merck, Northwest Biotherapeutics, Immutep Limited, Dendreon Corporation, Oncobiomed
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
178
Number of Tables & Figures
125
Customization Available
Yes, the report can be customized as per your need.
Global Dendritic Cell Cancer Vaccine Market Report Segments:
The global Dendritic Cell Cancer Vaccine market is segmented on the basis of:
Types
CreaVax, Sipuleucel-T (Provenge), Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pediatrics, Adults
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Activarti
- Argos Therapeutics
- SOTIO (Acquired by PPF Group)
- Bellicum Pharmaceuticals
- JW CreaGene
- DanDrit
- DCPrime
- Elios Therapeutics
- ImmunoCellular Therapeutics
- Kiromic
- Activarti
- Merck
- Northwest Biotherapeutics
- Immutep Limited
- Dendreon Corporation
- Oncobiomed
Highlights of The Dendritic Cell Cancer Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CreaVax
- Sipuleucel-T (Provenge)
- Others
- By Application:
- Pediatrics
- Adults
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dendritic Cell Cancer Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A dendritic cell cancer vaccine is a type of vaccine that uses cells from the patient's own body to help fight the disease. These vaccines work by helping the body's immune system recognize and attack cancer cells.
Some of the key players operating in the dendritic cell cancer vaccine market are Activarti, Argos Therapeutics, SOTIO (Acquired by PPF Group), Bellicum Pharmaceuticals, JW CreaGene, DanDrit, DCPrime, Elios Therapeutics, ImmunoCellular Therapeutics, Kiromic, Activarti, Merck, Northwest Biotherapeutics, Immutep Limited, Dendreon Corporation, Oncobiomed.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dendritic Cell Cancer Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dendritic Cell Cancer Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dendritic Cell Cancer Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dendritic Cell Cancer Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dendritic Cell Cancer Vaccine Market Size & Forecast, 2020-2028
4.5.1 Dendritic Cell Cancer Vaccine Market Size and Y-o-Y Growth
4.5.2 Dendritic Cell Cancer Vaccine Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 CreaVax
5.2.2 Sipuleucel-T (Provenge)
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Pediatrics
6.2.2 Adults
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dendritic Cell Cancer Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dendritic Cell Cancer Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 CreaVax
9.6.2 Sipuleucel-T (Provenge)
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Pediatrics
9.10.2 Adults
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 CreaVax
10.6.2 Sipuleucel-T (Provenge)
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Pediatrics
10.10.2 Adults
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 CreaVax
11.6.2 Sipuleucel-T (Provenge)
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Pediatrics
11.10.2 Adults
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 CreaVax
12.6.2 Sipuleucel-T (Provenge)
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Pediatrics
12.10.2 Adults
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 CreaVax
13.6.2 Sipuleucel-T (Provenge)
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Pediatrics
13.10.2 Adults
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dendritic Cell Cancer Vaccine Market: Competitive Dashboard
14.2 Global Dendritic Cell Cancer Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Activarti
14.3.2 Argos Therapeutics
14.3.3 SOTIO (Acquired by PPF Group)
14.3.4 Bellicum Pharmaceuticals
14.3.5 JW CreaGene
14.3.6 DanDrit
14.3.7 DCPrime
14.3.8 Elios Therapeutics
14.3.9 ImmunoCellular Therapeutics
14.3.10 Kiromic
14.3.11 Activarti
14.3.12 Merck
14.3.13 Northwest Biotherapeutics
14.3.14 Immutep Limited
14.3.15 Dendreon Corporation
14.3.16 Oncobiomed
